Clinical trial
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
NCT01947608
Study timeline
Registry last updated2020-11-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancer (NSCLC)unresolved
Interventions
LDK378DRUG
Sponsors & collaborators
Novartis Pharmaceuticalslead sponsor
Mapped research locations
BangkokThailand3AtlantaGeorgia, United States2SeoulSouth Korea2BostonMassachusetts, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1BaltimoreMaryland, United States1MiamiFlorida, United States1SeattleWashington, United States1Oklahoma CityOklahoma, United States1DetroitMichigan, United States1OmahaNebraska, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01947608 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.